Evidence-based·Updated November 19, 2026·How we grade evidence

Retatrutide

PeptideInvestigational weight-loss drug (not FDA-approved)

Retatrutide is an investigational once-weekly injection that acts on three hormone receptors. In published phase 3 trials lasting up to 80 weeks, adults with obesity lost on average 17.6% to 25.0% of their body weight depending on dose, compared with 3.9% on placebo, and it also reduced knee osteoarthritis pain and sleep apnea events. It is not FDA-approved, and its long-term safety and effects on heart attacks and strokes are not yet known.

Taking Retatrutide with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with obesity, with or without type 2 diabetes, who qualify for and choose to join a registered clinical trial (or, for a small group with severe obesity, the expanded access program a doctor can request); everyone else can ask a doctor about approved weight-loss medicines

Common dosing range

No approved dose. Phase 3 trials studied 4 mg, 9 mg or 12 mg injected once weekly; outside a trial no dose is established

When to expect effects

Weight loss built over many months; phase 3 results were measured at 40 to 80 weeks

Watch out for

Not FDA-approved and cannot be prescribed as a normal medicine. FDA says it cannot be used in compounding, and products sold online, including "research" vials, are unapproved and of unknown quality. In trials, stomach side effects were common and more people stopped the 9 mg dose than placebo because of side effects

What is it

Retatrutide is an investigational drug that is not FDA-approved for any use, so it cannot be prescribed as a normal medicine, and any product sold now as retatrutide (including vials labeled "for research use only") is unapproved and unverified. FDA says retatrutide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition; it has warned telehealth companies, ingredient distributors and outsourcing facilities for marketing, selling or repackaging it. Outside clinical trials, the only listed route is a single-patient expanded access program on ClinicalTrials.gov (NCT07629401), limited to adults with a BMI of 35 or more and at least two serious obesity-related complications that have not responded to the best approved treatment, who cannot join a trial. Its developer, Eli Lilly, is testing it in phase 3 trials as a once-weekly injection for obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea and other conditions. Several phase 3 trials have been published in 2026, and others, including a trial of heart and kidney outcomes and a head-to-head trial against tirzepatide, are still running on ClinicalTrials.gov.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You meet the entry criteria of a registered retatrutide trial (listed on ClinicalTrials.gov) and decide with the study team that you want to take part
You would rather wait to see whether FDA approves it and, meanwhile, discuss approved weight-loss or diabetes medicines with a prescriber
You have obesity with knee osteoarthritis pain or obstructive sleep apnea and want to follow the trial results with your doctor

Probably skip if…

You would be buying it online, from a telehealth service, a compounding pharmacy or a "research peptide" seller: FDA says these products are unapproved and of unknown quality
You have a personal or family history of medullary thyroid cancer or MEN 2, or you have had pancreatitis; people with these conditions were excluded from the trials
You are pregnant, trying to become pregnant or breastfeeding
You expect results without long-term follow-up: the trials lasted up to 80 weeks and outcomes after stopping are not published

Evidence at a glance

weight loss in adults with obesity without diabetes

Good Evidence
Effect
21.0 percentage points more weight loss than placebo with 12 mg and 19.8 points with 9 mg at 80 weeks (TRIUMPH-1)
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Time
Measured at 48 to 80 weeks; weight was still falling at 48 weeks in phase 2

weight and blood sugar in type 2 diabetes

Good Evidence
Effect
HbA1c 0.88 to 1.12 percentage points lower than placebo at 40 weeks; body weight 6.9 to 13.8 percentage points lower than placebo at 80 weeks
Best fit
Adults with type 2 diabetes and overweight or obesity on diet and exercise or oral diabetes medicines
Time
HbA1c measured at 24 to 40 weeks; weight at 36 to 80 weeks

knee osteoarthritis pain with obesity

Good Evidence
Effect
WOMAC pain 1.61 to 1.83 points lower than placebo at 68 weeks (hybrid estimand); 1.38 to 1.70 points (intention to treat)
Best fit
Adults with painful knee osteoarthritis and a BMI of 27 or more
Time
Measured at 68 to 80 weeks

obstructive sleep apnea with obesity

Good Evidence
Effect
21.9 to 24.4 fewer events an hour than placebo without diabetes; 14.4 to 15.1 fewer with type 2 diabetes (9 mg and 12 mg)
Best fit
Adults with moderate to severe sleep apnea and a BMI of 27 or more
Time
Measured at 80 weeks

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

weight loss in adults with obesity without diabetes

Disease adjunct
Good Evidence

In TRIUMPH-1, a phase 3 trial of 2339 adults with obesity and without diabetes, once-weekly retatrutide for 80 weeks lowered body weight by an average of 17.6% (4 mg), 23.7% (9 mg) and 25.0% (12 mg), compared with 3.9% on placebo. In TRIUMPH-4, 445 adults with obesity or overweight (BMI of 27 or more) and knee osteoarthritis lost 20.0% (9 mg) and 23.7% (12 mg) at 68 weeks, compared with 4.6% on placebo. In the earlier 48-week phase 2 trial of 338 adults, 83% of those on 12 mg lost at least 15% of their weight, compared with 2% on placebo. All three trials were funded by Eli Lilly. They did not test heart attacks, strokes or deaths, and no results after stopping the drug are published.

Effect size
21.0 percentage points more weight loss than placebo with 12 mg and 19.8 points with 9 mg at 80 weeks (TRIUMPH-1)
Time to effect
Measured at 48 to 80 weeks; weight was still falling at 48 weeks in phase 2
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Less likely
People with type 2 diabetes, who lost less weight in a separate trial; people under 18, who were not studied

Bottom line: Large average weight loss in phase 3 trials, but only up to 80 weeks and without heart outcome data.

weight and blood sugar in type 2 diabetes

Biomarker support
Good Evidence

In TRIUMPH-2, 1152 adults with obesity or overweight and type 2 diabetes (average HbA1c 7.71%) lost 11.9% (4 mg), 16.8% (9 mg) and 18.8% (12 mg) of their body weight over 80 weeks, compared with 5.1% on placebo. In TRANSCEND-T2D-1, 537 adults with type 2 diabetes not controlled by diet and exercise lowered HbA1c by 1.69 to 1.94 percentage points over 40 weeks, compared with 0.81 on placebo, and lost 11.5% to 15.3% of body weight, compared with 2.6%. In a 36-week phase 2 trial of 281 people in the USA, the 8 mg (slow step-up) and 12 mg doses lowered HbA1c more than dulaglutide 1.5 mg at 24 weeks. The trials were funded by Eli Lilly and did not measure diabetes complications.

Effect size
HbA1c 0.88 to 1.12 percentage points lower than placebo at 40 weeks; body weight 6.9 to 13.8 percentage points lower than placebo at 80 weeks
Time to effect
HbA1c measured at 24 to 40 weeks; weight at 36 to 80 weeks
Best fit
Adults with type 2 diabetes and overweight or obesity on diet and exercise or oral diabetes medicines
Less likely
People on insulin or with type 1 diabetes, who were not the focus of these published trials

Bottom line: It lowered blood sugar and weight in type 2 diabetes; effects on eye, kidney and heart complications are not yet known.

knee osteoarthritis pain with obesity

Disease adjunct
Good Evidence

In two phase 3 trials (TRIUMPH-4 with 445 adults and TRIUMPH-1-OA with 574 adults, all with painful knee osteoarthritis and obesity or overweight, without diabetes), retatrutide reduced the WOMAC knee pain score (0 to 10 scale) more than placebo. At 68 weeks in TRIUMPH-4 the pain score fell by 3.96 (9 mg) and 3.74 (12 mg), compared with 2.12 on placebo. Pain fell substantially on placebo too, so the extra benefit was about 1.4 to 1.8 points. Serious adverse events were more common with retatrutide than with placebo in both trials. The trials did not test joint structure or the need for knee replacement.

Effect size
WOMAC pain 1.61 to 1.83 points lower than placebo at 68 weeks (hybrid estimand); 1.38 to 1.70 points (intention to treat)
Time to effect
Measured at 68 to 80 weeks
Best fit
Adults with painful knee osteoarthritis and a BMI of 27 or more
Less likely
People with joint disease other than osteoarthritis, or without excess weight, who were not studied

Bottom line: Knee pain eased more than with placebo, alongside large weight loss; whether the joint itself changes is unknown.

obstructive sleep apnea with obesity

Disease adjunct
Good Evidence

In two phase 3 trials nested inside TRIUMPH-1 (243 adults without diabetes) and TRIUMPH-2 (448 adults with type 2 diabetes), all with moderate to severe sleep apnea (about 56 to 59 breathing events an hour at the start), retatrutide lowered the apnea-hypopnea index more than placebo over 80 weeks. Without diabetes, events fell by 34.3 an hour on 9 mg and 31.7 on 12 mg, compared with 9.9 on placebo; with diabetes, by 24.7 and 25.4, compared with 10.3. The trials were funded by Eli Lilly. On average, people still had more than 20 events an hour at the end, which is still sleep apnea.

Effect size
21.9 to 24.4 fewer events an hour than placebo without diabetes; 14.4 to 15.1 fewer with type 2 diabetes (9 mg and 12 mg)
Time to effect
Measured at 80 weeks
Best fit
Adults with moderate to severe sleep apnea and a BMI of 27 or more
Less likely
People with mild sleep apnea or without excess weight, who were not studied

Bottom line: Fewer breathing pauses at night than placebo; on average, sleep apnea was still present at the end.

How it works

Retatrutide is a single peptide that activates three hormone receptors: GIP and GLP-1, the two targets of tirzepatide, plus the receptor for glucagon. GLP-1 and GIP signals reduce appetite and help the body release insulin after meals. Glucagon is a hormone that normally raises blood sugar, but in this combination its receptor is targeted to increase energy use and act on the liver, which is the reason researchers added it. It is injected under the skin once a week. Like the approved GLP-1 medicines, it slows stomach emptying, which helps explain both the reduced appetite and the stomach side effects. In the phase 2 obesity trial, heart rate rose with higher doses, peaked at 24 weeks and declined afterward.

How to take it

1. Typical dose
There is no approved dose. In the phase 3 trials, participants received 4 mg, 9 mg or 12 mg of retatrutide injected under the skin once a week. These are studied doses, not recommendations; outside a trial no dose is established, and in a trial the study team sets it.
2. Higher studied dose
12 mg once weekly is the highest dose in the phase 3 trials. In the phase 2 obesity trial, starting at 2 mg rather than 4 mg partly reduced stomach side effects; the phase 3 abstracts do not give the step-up schedule.
3. Timing
Once a week by injection under the skin in trials
4. With food
Food instructions have not been established for this investigational drug
5. Split dosing
Not studied; trials used one weekly injection
6. How long to try
Phase 3 trials lasted 40 to 80 weeks. There are no published long-term data and no published results on weight after stopping

What to track

In a trial, the study visits and blood tests the study team schedules
Nausea, vomiting or diarrhea, and signs of dehydration such as dizziness or very little urine
Severe stomach pain that does not go away, with or without vomiting (a possible sign of pancreatitis in this drug class): get urgent care
Dizziness or lightheadedness (low blood pressure was more common on retatrutide in a phase 3 trial)
Unusual skin sensations such as tingling or burning (dysesthesia was more common on retatrutide)
Low blood sugar symptoms if you also take insulin or a sulfonylurea

Bottom line: Large weight losses in trials, but it is an unapproved drug: a registered clinical trial (or, for a small group with severe obesity, a doctor-requested expanded access program) is the only legitimate route now.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Diarrhea (27% to 34% vs 13% on placebo in TRIUMPH-2)Nausea (14% to 28% vs 8% on placebo in TRIUMPH-2)Vomiting and constipation, mostly mild to moderate (stomach side effects were dose-related in the phase 2 trial)Unusual skin sensations such as tingling or burning (dysesthesia: 4% to 7% vs 1% on placebo in TRIUMPH-2)Low blood pressure (1% to 6% vs under 1% on placebo in TRIUMPH-2)Faster heart rate, which peaked at 24 weeks in the phase 2 trial

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: no data on retatrutide in pregnancy are published. As a class warning, the labels of approved weight-loss drugs in this family say they may cause fetal harm; the Zepbound (tirzepatide) label says to stop when pregnancy is recognized. Breastfeeding: no data on retatrutide in breast milk or in breastfed infants are published.

Interactions

Insulin and sulfonylureas (such as glipizide, glyburide or glimepiride)High

Class-based, not a finding for retatrutide: the Wegovy (semaglutide) and Zepbound (tirzepatide) labels say that use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. Retatrutide has no FDA label. In the published trial of retatrutide alone in type 2 diabetes (TRANSCEND-T2D-1), no severe low blood sugar was reported.

Semaglutide, tirzepatide or other GLP-1 medicinesHigh

Class-based, not a finding for retatrutide: retatrutide acts on the GLP-1 receptor. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. TRIUMPH-1 excluded people who had taken weight-loss drugs in the 90 days before screening.

Oral medicines with a narrow safety margin (such as warfarin) and birth control pillsModerate

Class-based, not a finding for retatrutide: the Zepbound label says tirzepatide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to monitor people taking oral medicines with a narrow therapeutic index (for example warfarin); the Wegovy label says to consider increased clinical or laboratory monitoring with such medicines. A study of retatrutide with warfarin, midazolam and caffeine is listed as completed on ClinicalTrials.gov (NCT05445232), but no results are posted or published. The Zepbound label also advises people using birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. A study of retatrutide with a combined birth control pill is listed as completed on ClinicalTrials.gov (NCT06039826), but no results are posted or published.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

The legitimate sources today are a registered clinical trial (listed on ClinicalTrials.gov with an NCT number, with the study drug supplied by the trial) or Lilly's single-patient expanded access program (NCT07629401), which a doctor requests for adults with severe obesity who meet its criteria
In a trial you sign an informed consent form that names the sponsor, the study doctor and what is being tested
No pharmacy, compounder or telehealth service can lawfully supply FDA-approved retatrutide, because no approved product exists

Be skeptical of…

"For research use only" or "not for human consumption" vials sold to the public: FDA has warned companies selling retatrutide this way for human use
"Compounded retatrutide": FDA says retatrutide cannot be used in compounding under federal law
"FDA-registered" or "has an NDC number, so it is approved": FDA says assignment of an NDC number does not denote FDA approval. The retatrutide listings on DailyMed come from an e-commerce company and are marked "Export only"; they are not approvals
"Clinically proven safe": trials lasted up to 80 weeks, and heart outcome results are not yet available
"The same as in the Lilly trials": FDA says products sold as "research" retatrutide are of unknown quality, and warns that illegally marketed GLP-1 drugs sold online may be counterfeit or contain the wrong ingredient or amount
Dosing charts or "microdosing" schedules from sellers: no dose is approved, and the phase 3 trials studied 4, 9 and 12 mg weekly under medical supervision

Frequently asked questions

Is retatrutide FDA-approved?⌄

No. As of November 19, 2026, it does not appear among FDA's approved drugs, and FDA states that it is not a component of any FDA-approved drug and has not been found safe and effective for any condition. It is in phase 3 trials run by Eli Lilly. Only FDA can decide whether it is approved.

Is it legal to buy retatrutide online?⌄

Retatrutide is an unapproved drug. FDA says it cannot be used in compounding under federal law, and it has warned telehealth companies, ingredient distributors and sellers of "research" products for marketing it. FDA urges people not to buy these products, which are of unknown quality. A registered clinical trial is the main legitimate way to receive it now; Lilly also lists a single-patient expanded access program (NCT07629401) that a doctor can request only for adults with severe obesity who meet strict criteria and cannot join a trial.

How does retatrutide compare with tirzepatide or semaglutide?⌄

It acts on the same GLP-1 and GIP receptors as tirzepatide plus the glucagon receptor. In its phase 3 obesity trial, average weight loss at 80 weeks was 23.7% on 9 mg and 25.0% on 12 mg. Numbers from different trials cannot be compared directly, though: a head-to-head trial against tirzepatide (TRIUMPH-5) is listed on ClinicalTrials.gov and its results are not published yet.

Can I join a retatrutide trial?⌄

Trials are listed on ClinicalTrials.gov, including some still recruiting. Each trial has its own entry rules: for example, TRIUMPH-1 excluded people with diabetes, a history of pancreatitis, or a personal or family history of medullary thyroid cancer or MEN 2. Your doctor can help you judge whether a trial fits you.

Can I take retatrutide with my supplements or other medicines?⌄

No interaction studies of retatrutide with supplements have been published. Based on the labels of approved drugs in the same family, low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.

Does the weight stay off after stopping?⌄

That is not known yet. No published retatrutide trial has reported what happens after the drug is stopped. In SURMOUNT-4, a withdrawal trial of the approved drug tirzepatide published in JAMA in 2024, adults who switched to placebo after 36 weeks of treatment regained an average of 14.0% of their body weight over the next 52 weeks, while those who stayed on tirzepatide lost a further 5.5%. A retatrutide trial of weight maintenance (TRIUMPH-6) is listed on ClinicalTrials.gov.

References by claim

weight loss in adults with obesity without diabetes

Jastreboff et al., 2026 · PubMed (2026) link

Schnitzer et al., 2026 · PubMed (2026) link

Jastreboff et al., 2023 · PubMed (2023) link

weight and blood sugar in type 2 diabetes

Bellido et al., 2026 · PubMed (2026) link

Bajaj et al., 2026 · PubMed (2026) link

Rosenstock et al., 2023 · PubMed (2023) link

obstructive sleep apnea with obesity

Grunstein et al., 2026 · PubMed (2026) link

Safety

ClinicalTrials.gov record NCT06383390: effect of retatrutide on cardiovascular and kidney outcomes · ClinicalTrials.gov link

Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link

ClinicalTrials.gov record NCT05929066 (TRIUMPH-1): eligibility criteria · ClinicalTrials.gov link

Wegovy (semaglutide) injection and tablets prescribing information · DailyMed (FDA label) link

FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss · FDA link

ClinicalTrials.gov record NCT07629401: pre-approval single-patient expanded access of retatrutide · ClinicalTrials.gov link

Interaction: Oral medicines with a narrow safety margin (such as warfarin) and birth control pills

ClinicalTrials.gov record NCT05445232: drug interaction study of LY3437943 (retatrutide) with midazolam, warfarin and caffeine · ClinicalTrials.gov link

ClinicalTrials.gov record NCT06039826: effect of LY3437943 (retatrutide) on a combined oral contraceptive · ClinicalTrials.gov link

Track Retatrutide with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.